Phase 1 Investor is our most exclusive and expensive investment advisory at Stansberry Research. Written by our resident biotech expert Rob Fannon, the service primarily focuses on emerging technologies that have a clear and rapid course towards commercialization in the healthcare, life science, and biotechnology industries.

Rob has considerable experience in business and science, a necessary attribute for an investor in healthcare and biotechnology. He holds a Masters degree in public health and an MBA, both from Johns Hopkins University. He has also helped open a new biotechnology company in India. Rob’s recommendations are some of the best research we’ve published. His top winners include 203% on Sirna, 215% on ID Biomedical.

To help him out with Phase 1 research, Rob hired Dr. George Huang to join his team. George’s specialty is getting exclusive information from top universities, labs, and venture capital firms on new technologies in the health sector. He holds a PhD from Johns Hopkins’ School of Medicine, where he worked under a 2003 Nobel Laureate in Chemistry.

We pay a premium for Rob and George's specialized knowledge. This is why Phase 1 Investor is our most expensive research service, and why it's also our most successful one.

Click here to learn more.